Serological response to COVID-19 vaccination in patients with cancer older than 80 years

Central studies carried out on vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-COV2) excluded patients receiving immunosuppressive therapy and those diagnosed with an immunosuppressive condition. Moreover, there are no data on vaccine efficacy regarding older patients with cancer.ObjectivesThe primary objective was to evaluate the seroprevalence of the SARS-CoV2 IgG in older patients (aged ≥80 years) diagnosed with solid or hematological malignancies, one month after administering the second dose of the BNT162b2 vaccine.Materials and methodsWe screened 74 older patients with cancer, 45 of them accepted to receive the vaccination and collected serum samples from 36 patients; a group of medical doctors and nurses from our hospital was used as a control in a 1:2 ratio.ResultsThe median age was 82 years (range 80–89). Median serum IgG were 2396,10 AU/ml (range 0–32,763,00) in patients with cancer and 8737,49 AU/ml (398.90–976,280,00) in the control group, p < 0.0001. Additional subgroup analyses were performed comparing males and females, patients treated with chemotherapy versus other therapies (immunotherapy, targeted therapy), solid tumors versus hematological malignancies, early (I-II) versus advanced (III-IV) stage of disease, continuative corticosteroid use or not. None of them reached statistical significance.ConclusionOur study shows for the first time that patients with cancer aged ≥80 years can have a serological response to the BNT162b2 COVID-19 vaccine one month after vaccination and consequently support the vaccination campaign currently underway in this frail population.     

Seroconversion rates following COVID-19 vaccination among patients with cancer

1. Download : Download high-res image (139KB)
2. Download : Download full-size image

     

COVID-19 vaccination and breast cancer surgery timing

Breast Cancer Research and Treatment - There have been recent reports in the breast imaging literature of unilateral axillary lymphadenopathy following COVID-19 vaccination. It is unclear whether...     

老年癌症患者的化疗耐受性与安全性分析

肿瘤在60岁以后发病率显著增加。随着我国人口结构的老年化，老年肿瘤患者越来越多，其对化疗的耐受性及安全性有待深入了解。本文介绍了老年患者的药代动力学和药效学特点以及老年患者化疗常见的毒副作用，另外还介绍了老年综合评价的内容及重要性。就老年常见肿瘤化疗的有效性及安全性做了重点介绍并分析了各种研究结论之间差异的原因。